{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:03:11Z","timestamp":1789707791261,"version":"4.0.1"},"reference-count":28,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University\u2014Sofia"},{"id":[{"id":"https:\/\/ror.org\/01n9zy652","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: The pivotal ARCHES trial demonstrated the clinical benefit of the second-generation androgen receptor signaling inhibitor enzalutamide in combination with androgen deprivation therapy (ADT) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). However, real-world evidence on the efficacy of enzalutamide plus ADT in mHSPC remains very limited. The current work provides real-world data on the efficacy of this combination in a Bulgarian cohort of patients with mHSPC. Methods: Patients treated with enzalutamide plus ADT across 48 hospitals between 1 January 2022 and 31 December 2025 were included in our retrospective analysis. Data were extracted from electronic health records, for which large language model (LLM) algorithms were employed, utilizing the Danny Platform (Sqilline Health, Sofia, Bulgaria). Treatment outcome was evaluated based on overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and clinical benefit rate (CBR). Iterative proportional fitting was performed to improve comparability between the real-world and trial populations by accounting for differences in baseline characteristics. Results: Baseline characteristics were largely comparable among the ARCHES and our real-world cohort, with the most notable differences observed in prior systemic treatment exposure. A considerably higher ORR was reported for ARCHES (85.9%) in contrast to our cohort descriptive ORR (12.3%) derived from physician EHR notes, likely reflecting routine clinical documentation practices, whereas CBR values were comparable (89.6% in our cohort versus 95.9% in ARCHES). While median values were not calculable, estimated PFS and OS were consistent with those in ARCHES. Conclusions: Real-world outcomes from our Bulgarian cohort of patients with mHSPC are largely consistent with those observed among enzalutamide-treated participants in the ARCHES trial.<\/jats:p>","DOI":"10.3390\/cancers18183007","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:07:29Z","timestamp":1789574849000},"page":"3007","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enzalutamide Plus ADT for the Treatment of mHSPC: Real-World Evidence from a Bulgarian Cohort"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8749-7974","authenticated-orcid":false,"given":"Manoela","family":"Manova","sequence":"first","affiliation":[{"name":"Department of Organization and Economy of Pharmacy, Faculty of Pharmacy, Medical University, 1000 Sofia, Bulgaria"},{"name":"National Council on Prices and Reimbursement of Medicinal Products, 1431 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2466-9254","authenticated-orcid":false,"given":"Boryana","family":"Ivanova","sequence":"additional","affiliation":[{"name":"Department of Organization and Economy of Pharmacy, Faculty of Pharmacy, Medical University, 1000 Sofia, Bulgaria"},{"name":"National Council on Prices and Reimbursement of Medicinal Products, 1431 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0163-6479","authenticated-orcid":false,"given":"Antoan","family":"Rangelov","sequence":"additional","affiliation":[{"name":"National Council on Prices and Reimbursement of Medicinal Products, 1431 Sofia, Bulgaria"},{"name":"Faculty of Chemistry and Pharmacy, Sofia University \u201cSt. Kliment Ohridski\u201d, 1164 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mila","family":"Petrova","sequence":"additional","affiliation":[{"name":"Medical Oncology Clinic, Multiprofile Hospital for Active Treatment (MHAT) Nadezhda, 1330 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assen","family":"Dudov","sequence":"additional","affiliation":[{"name":"Medical Oncology Clinic, Acibadem City Clinic Mladost (UMHAT), 1784 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivsan","family":"Chan","sequence":"additional","affiliation":[{"name":"Medical Oncology Clinic, Acibadem City Clinic Mladost (UMHAT), 1784 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevil","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Medical Oncology Clinic, Acibadem City Clinic Mladost (UMHAT), 1784 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Nenov","sequence":"additional","affiliation":[{"name":"Medical Oncology Clinic, Acibadem City Clinic Mladost (UMHAT), 1784 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elitsa","family":"Varbanova","sequence":"additional","affiliation":[{"name":"Medical Oncology Clinic, Acibadem City Clinic Mladost (UMHAT), 1784 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6932-0885","authenticated-orcid":false,"given":"Todor","family":"Georgiev","sequence":"additional","affiliation":[{"name":"Sqilline Health, 1766 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9971-9466","authenticated-orcid":false,"given":"Daniel","family":"Penchev","sequence":"additional","affiliation":[{"name":"Sqilline Health, 1766 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4579-5524","authenticated-orcid":false,"given":"Alexandra","family":"Savova","sequence":"additional","affiliation":[{"name":"Department of Organization and Economy of Pharmacy, Faculty of Pharmacy, Medical University, 1000 Sofia, Bulgaria"},{"name":"National Council on Prices and Reimbursement of Medicinal Products, 1431 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"ref_1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.eururo.2016.05.043","article-title":"Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries","volume":"70","author":"Wong","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.eururo.2016.10.008","article-title":"Global Burden of Urologic Cancers, 1990\u20132013","volume":"71","author":"Dy","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00345-011-0801-1","article-title":"Familial risk and familial survival in prostate cancer","volume":"30","author":"Hemminki","year":"2012","journal-title":"World J. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Familial Risk and Heritability of Cancer Among Twins in Nordic Countries","volume":"315","author":"Mucci","year":"2016","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/jnci\/djac158","article-title":"Estimation of the Number of Individuals Living with Metastatic Cancer in the United States","volume":"114","author":"Gallicchio","year":"2022","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/1055-9965.EPI-22-1038","article-title":"Estimating the Number of Men Living with Metastatic Prostate Cancer in the United States","volume":"32","author":"Devasia","year":"2023","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","article-title":"Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019","volume":"77","author":"Gillessen","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy with Enzalutamide or Placebo in Men with Metastatic Hormone-Sensitive Prostate Cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved Survival with Enzalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/JU.0000000000001568","article-title":"Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses","volume":"205","author":"Armstrong","year":"2021","journal-title":"J. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"(2023). LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer. J. Urol., 210, 224\u2013226.","DOI":"10.1097\/JU.0000000000003518"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41391-025-01067-3","article-title":"Enzalutamide in metastatic hormone-sensitive prostate cancer: Results from the international, multicentre, real-world ARON-3 study","volume":"29","author":"Rizzo","year":"2026","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/jjco\/hyag042","article-title":"Real-world comparison of enzalutamide and apalutamide in metastatic hormone-sensitive prostate cancer: A multi-institutional propensity score-matched analysis","volume":"56","author":"Nishimura","year":"2026","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1200\/OP-24-00690","article-title":"Real-World Evidence of Combination Therapy Use in Metastatic Hormone-Sensitive Prostate Cancer in the United States from 2017 to 2023","volume":"21","author":"Raval","year":"2025","journal-title":"JCO Oncol. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1200\/JCO.2024.42.4_suppl.51","article-title":"Real-world comparison of prostate-specific antigen (PSA) response in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or enzalutamide (ENZ)","volume":"42","author":"Lowentritt","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1200\/JCO.19.02035","article-title":"Informing Patients About Expected Outcomes: The Efficacy-Effectiveness Gap","volume":"38","author":"Templeton","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_24","first-page":"73","article-title":"WHICH PATIENTS WILL BENEFIT MOST FROM DOCETAXEL ADDITION TO ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER (MCSPC)?","volume":"58","author":"Gamulin","year":"2019","journal-title":"Acta Clin. Croat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1200\/JCO.20.03256","article-title":"Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update","volume":"39","author":"Virgo","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1097\/JU.0000000000002038.07","article-title":"PD34-07 ENZALUTAMIDE IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER PATIENTS WHO RECEIVED PRIOR ANTIANDROGEN THERAPY: POST HOC ANALYSIS OF ARCHES","volume":"206","author":"Shore","year":"2021","journal-title":"J. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"oyaf182","DOI":"10.1093\/oncolo\/oyaf182","article-title":"Regarding RECIST in retrospective studies","volume":"30","author":"Wu","year":"2025","journal-title":"Oncologist"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S776","DOI":"10.1016\/S0302-2838(22)00600-5","article-title":"Clinical outcomes of patients with metastatic Hormone-Sensitive Prostate Cancer (mHSPC) with Prostate-Specific Antigen (PSA) decline to undetectable levels on enzalutamide (ENZA): Post hoc analysis of ARCHES","volume":"81","author":"Stenzl","year":"2022","journal-title":"Eur. Urol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/3007\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:15:52Z","timestamp":1789704952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/3007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":28,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18183007"],"URL":"https:\/\/doi.org\/10.3390\/cancers18183007","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}